title: Rizatriptan 5 mg for the acute treatment of migraine in adolescents: results from a double-blind, single-attack study and two open-label, multiple-attack studies.
authors.affiliation: Merck Research Laboratories, West Point, PA 19486, USA.
authors.forename: W Hester
authors.initials: WH
authors.lastname: Visser
authors.forename: Paul
authors.initials: P
authors.lastname: Winner
authors.forename: Kim
authors.initials: K
authors.lastname: Strohmaier
authors.forename: Meghan
authors.initials: M
authors.lastname: Klipfel
authors.forename: Yahong
authors.initials: Y
authors.lastname: Peng
authors.forename: Kathleen
authors.initials: K
authors.lastname: McCarroll
authors.forename: Roger
authors.initials: R
authors.lastname: Cady
authors.forename: Donald
authors.initials: D
authors.lastname: Lewis
authors.forename: Robert
authors.initials: R
authors.lastname: Nett
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008881:Migraine Disorders / Q000188:drug therapy*; D012008:Recurrence; D017366:Serotonin Receptor Agonists / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome; D014230:Triazoles / Q000009:adverse effects / Q000627:therapeutic use*; D014363:Tryptamines
chemical_list: D017366:Serotonin Receptor Agonists; D014230:Triazoles; D014363:Tryptamines; C093622:rizatriptan